TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 2, 2017, the Board of Directors (the “Board”) of Trevena, Inc. (the “Company”) (i) approved a cash incentive award for fiscal year 2016 under the Trevena, Inc. Incentive Compensation Plan (the “ICP”) to be made to Maxine Gowen, Ph.D., the President and Chief Executive Officer (the “CEO”) of the Company, and (ii) ratified ICP cash incentive awards for fiscal year 2016 that were approved by the Compensation Committee of the Board for the Company’s executive officers other than the CEO. The individual ICP awards earned in 2016 will be paid in mid-March 2017, as follows: Maxine Gowen, Ph.D., $260,000; Carrie Bourdow, $116,025; Roberto Cuca, $149,172; Yacoub Habib, Ph.D., $115,290; Michael W. Lark, Ph.D., $126,017; John M. Limongelli, $116,550; and David Soergel, M.D., $128,275.


About TREVENA, INC. (NASDAQ:TRVN)

Trevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.

TREVENA, INC. (NASDAQ:TRVN) Recent Trading Information

TREVENA, INC. (NASDAQ:TRVN) closed its last trading session up +0.04 at 4.17 with 1,950,858 shares trading hands.